October 24, 2021

China Biologic suffers contaminated infusion

Pin It

By Jeffrey Goldfarb Reuters¬† From Nasdaq (The author is a Reuters Breakingviews columnist.) HONG KONG, Aug 27 (Reuters Breakingviews) – China Biologic Products makes a good case for why it should go private. Instead of accepting one of two takeover bids offering hefty premiums, the U.S.-listed manufacturer of plasma products opted for a dilutive share […]